HPMC Sustained-Release Calcium Alpha-Ketoglutarate for Predictable Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery methods for calcium alpha-ketoglutarate (Ca-AKG) result in rapid release, leading to spikes in blood concentration and increased frequency of administration, with variable and low bioavailability when released in the stomach or upper gastrointestinal tract, making dosing unpredictable and clinical outcomes less predictable.
Innovation Solution
Development of controlled-release, sustained-release formulations of Ca-AKG using hydroxypropylmethylcellulose (HPMC) with specific molecular weights to control the release rate, allowing for lower doses to achieve similar outcomes with higher overall bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation of Ca-AKG is used, then rapid release and spike in blood concentration is achieved, but bioavailability is variable and low, leading to increased frequency of administration
Solution Approach 1:
The patent changes the release rate parameter by formulating Ca-AKG with controlled-release matrices (HPMC, Eudragit, or wax coatings) that modify the dissolution characteristics. This transforms the immediate-release formulation into a sustained-release formulation, maintaining Ca-AKG levels within a therapeutic window and improving bioavailability predictability.
Solution Approach 2:
The patent introduces controlled-release matrices as intermediary substances between the Ca-AKG and the gastrointestinal tract. These matrices (HPMC, Eudragit, or waxes) act as mediators that control the release kinetics, preventing rapid dissolution and improving the reliability of Ca-AKG delivery.
2Speed
If immediate release formulation of Ca-AKG is used, then rapid release is achieved, but dosing predictability and clinical outcome consistency are reduced
Solution Approach 1:
The patent modifies the release rate parameter through controlled-release formulation techniques, transforming unpredictable immediate release into predictable sustained release. This allows for more precise dosing regimens and consistent clinical outcomes.
Solution Approach 2:
The controlled-release matrices provide a feedback mechanism where the release rate is automatically regulated by the matrix properties (viscosity, crystallinity, coating thickness), ensuring consistent dosing without requiring complex monitoring or adjustment.
3Quantity of substance
If higher doses of Ca-AKG are administered to compensate for low bioavailability, then therapeutic effect is achieved, but frequency of administration increases
Solution Approach 1:
The controlled-release formulation ensures continuous delivery of Ca-AKG over an extended period, maintaining therapeutic levels without requiring frequent re-administration. This transforms discontinuous dosing into continuous therapeutic action.
Solution Approach 2:
The sustained-release formulation delivers Ca-AKG at a controlled, partial rate over time rather than in a single excessive dose, achieving the same cumulative therapeutic effect while extending the duration of action and reducing administration frequency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The controlled-release formulations provide predictable dosing and improved bioavailability, enabling lower doses to achieve therapeutic effects while maintaining consistent plasma levels over time.
Implementation Method 1
A controlled release, sustained release, and/or delayed release formulation of Ca-AKG has been discovered
Data Source
AI summary
In certain embodiments, sustained-release compositions of alpha- ketoglutarate are described herein.